Energenesis Biomedical Co Ltd (TWSE:6657), a clinical-stage biopharmaceutical company focused on restoring cellular energy, announced on Monday that it presented at the Taiwan Space International Conference & Industry Expo (TASTI 2026), which runs from 8-11 November 2026 at the International Convention Center in Tainan, Taiwan.

This year's theme is 'Trusted in Space, Resilient on Earth'. The company's presentation, 'ATP: Powering Human Health Beyond Earth', introduced its commitment to developing an innovative solution for space anaemia, a condition associated with accelerated red blood cell destruction in microgravity.

According to Energenesis, as commercial spaceflight expands and agencies prepare for missions to the Moon and Mars, the physiological effects of microgravity are a growing concern. A 2022 study of 14 astronauts on six-month space missions, published in Nature Medicine, found that their bodies destroyed about 54% more red blood cells in space than on Earth. Prof. Yi-Chiung Hsu of National Central University (NCU), which hosted the TASTI forum on space biomedicine, said that microgravity, radiation exposure and circadian-rhythm disruption may affect the immune system, cardiovascular function, bone metabolism and muscle strength, and that integrating biomedicine, engineering and artificial intelligence to build effective health monitoring and protection is an important challenge for future deep-space exploration.

Dr. Han-Min Chen, Energenesis Biomedical chairman and CEO, spoke in the forum session 'Beyond Earth, Beyond Limits: Innovations in Space Biomedicine and Human Health'. In the presentation, Energenesis reported experimental results indicating that ENERGI, the company's proprietary small-molecule platform, replenishes adenine, a molecule naturally present in human cells. This activates AMPK, a key enzyme that regulates cellular energy, and raises cellular ATP. In simulated extreme space environments, the company reported that higher ATP levels in red blood cells and surrounding cells were associated with greater red blood cell stability and resilience.

The mechanism studied for space anaemia may also be applied to clinical medicine on Earth. For patients who experience red blood cell loss and muscle atrophy due to prolonged bed rest, ageing or critical illness, ENERGI's approach of raising cellular ATP to support the body's own cell repair may offer a promising new option for prevention and treatment, Energenesis said.